Photocure ASA: Initiation of a share buyback

19 Mar 2025 18:00 CET

Oslo, Norway, 19 March 2025: Photocure ASA (the "Company") has decided to
initiate a buyback of up to 200,000 of its own shares for a total maximum amount
of NOK 20 million. The buyback program may be carried out in the period from
this announcement and until 5 May 2025.

The buybacks will be made in accordance with the authorisation granted to the
board of directors by the Company`s annual general meeting held on 23 May 2024
(the "Authorisation") and in accordance with principles of the Market Abuse
Regulation (EU) No 596/2014 and Commission Delegated Regulation (EU) No.
2016/1052 regarding exemptions from market manipulation, insider trading, and
the disclosure of inside information for share repurchase programs.

The Company considers the shares to represent an attractive value at current
levels. The purpose of the program is to acquire shares, at what the Company
believes are attractive prices, that will be used to fulfil obligations arising
in accordance with Photocure's long term incentive programs and/or reduce shares
outstanding.

According to the Authorisation, the Company`s own shares may be purchased at a
minimum of NOK 0.50 and a maximum of NOK 250 per share. The Authorisation is
valid until the annual general meeting in 2025, and no later than 30 June 2025.

The Company has engaged DNB Markets, a part of DNB Bank ASA, to manage and carry
out the share buyback program. All acquisitions under the buyback program will
be executed on Euronext Oslo Børs by DNB Markets, independently of the Company.
The execution of any repurchases may be discontinued at any time and the Company
may resolve to terminate the buyback program before the threshold set out above
is reached.

Photocure owns 314,148 own shares in the Company as of the date of this
Announcement. As of the date of this announcement, the Company has acquired
300.000 shares pursuant to the Authorisation.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA Photocure:
The Bladder Cancer Company delivers transformative solutions to improve the
lives of bladder cancer patients. Our unique technology, making cancer cells
glow bright pink, has led to better health outcomes for patients worldwide.
Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (OSE: PHO). For more information, please visit us at www.photocure.com
and www.cysview.com. All trademarks mentioned in this release are protected by
law and are registered trademarks of Photocure ASA.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is made public by Photocure ASA pursuant to the EU Market Abuse
Regulation and subject to the disclosure requirements pursuant to Section 5-12
of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site